These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 6202621)

  • 1. Clinical studies with propafenone--a new antiarrhythmic agent.
    Prabhakaran SN; Bhatia ML
    Indian Heart J; 1984; 36(2):107-10. PubMed ID: 6202621
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effectiveness of propafenon and disopyramide in ventricular extrasystole. Comparative study].
    Kenedi P
    MMW Munch Med Wochenschr; 1982 Aug; 124(34):734-6. PubMed ID: 6182460
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapeutic usefulness of propafenone in threatening ventricular extrasystolic arrhythmias controlled with Holter ECG].
    Ferrara E; Vitali A; Cucchi GF
    Minerva Cardioangiol; 1985 Sep; 33(9):553-6. PubMed ID: 2418385
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of chronic ventricular extrasystole with propafenone (Rhythmonorm)].
    Dimitrov D
    Vutr Boles; 1984; 23(4):65-9. PubMed ID: 6209861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of cardiac arrhythmias in the aged and their treatment with propafenone controlled by plasma level].
    Lachnit KS; Rieder L
    Z Gerontol; 1985; 18(6):343-52. PubMed ID: 2420079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of anti-arrhythmia agents].
    Klein G; Wirtzfeld A; Schlegl J; Himmler C; Neiss A
    Med Klin; 1980 Nov; 75(24):853-5. PubMed ID: 6160379
    [No Abstract]   [Full Text] [Related]  

  • 7. [Antiarrhythmic efficacy of mexiletine, propafenone and flecainide in ventricular premature beats. A comparative study in patients after myocardial infarction (author's transl)].
    Klempt HW; Nayebagha A; Fabry E
    Z Kardiol; 1982 May; 71(5):340-9. PubMed ID: 6180562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Propafenone in ventricular hyperkinetic arrhythmias. Dynamic ECG evaluation of the acute oral test and short-term treatment].
    Garimoldi M; Sghirinzetti M; Pirastu A; Cappiello E; Sala R; Terranova P
    G Ital Cardiol; 1986 Apr; 16(4):328-32. PubMed ID: 2427383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical experiences with a new anti-arrhythmia agent propafenon].
    Seipel L; Fischer G; Wiebringhaus E
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1229-31. PubMed ID: 70898
    [No Abstract]   [Full Text] [Related]  

  • 10. [Value of propafenon in the control of ventricular extrasystolic arrhythmia. Clinical, electrocardiographic and laboratory evaluation in prolonged use].
    Giannini SD; Zillioto EE; Campanari JC; Formicola A
    Arq Bras Cardiol; 1980 Dec; 35(6):525-8. PubMed ID: 6167246
    [No Abstract]   [Full Text] [Related]  

  • 11. [Oral propafenone in the long-term treatment of chronic ventricular arrhythmia].
    Vázquez García A; Marcos Sánchez F; Górgolas Hernández-Mora P; Durán Pérez-Navarro A
    Rev Clin Esp; 1986 Jun; 179(2):101. PubMed ID: 3738054
    [No Abstract]   [Full Text] [Related]  

  • 12. [Indications and risks of anti-arrhythmia treatment with propafenone (author's transl)].
    Beck OA; Hochrein H
    Dtsch Med Wochenschr; 1978 Aug; 103(32):1261-5. PubMed ID: 78793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of new antiarrhythmic agents: experiences with propafenone.
    Furlanello F; Disertori M; Vergara G; Guarnerio M; Dal Forno P; Padrini R; Gobbato S; Ferrari M
    Int J Clin Pharmacol Res; 1983; 3(2):101-5. PubMed ID: 6679511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Holter monitoring comparative assessment of propafenone and dihydroquinidine efficacy in the treatment of premature ventricular beats.
    Rizzon P; De Toma L; Mangini SG; Scrutinio D; Lagioia R; De Nicolò M
    Cardiologia; 1983 Sep; 28(9):791-801. PubMed ID: 6398703
    [No Abstract]   [Full Text] [Related]  

  • 15. [Plasma level and effectiveness of propafenone and its organ distribution (author's transl)].
    Blanke H; Aschbrenner B; Karsch KR; Kreuzer H
    Dtsch Med Wochenschr; 1979 Apr; 104(16):587-91. PubMed ID: 86416
    [No Abstract]   [Full Text] [Related]  

  • 16. [Propafenon in ventricular arrhythmia caused by ischemic cardiopathy. Quantitative study using the Holter system].
    de Brito FS; Pereira MH; Castro I; Maia IG
    Arq Bras Cardiol; 1979 Oct; 33(4):303-10. PubMed ID: 94993
    [No Abstract]   [Full Text] [Related]  

  • 17. [Propafenone--a new antiarrhythmic agent. Clinical experience].
    Kozák P; Stárek A; Hes I; Spacek R
    Cas Lek Cesk; 1985 Mar; 124(13):407-10. PubMed ID: 3891090
    [No Abstract]   [Full Text] [Related]  

  • 18. [Holter analysis of ventricular arrhythmias and its treatment with propafenone].
    Peralta Heredia R
    Arch Inst Cardiol Mex; 1986; 56(3):225-30. PubMed ID: 2428317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Propafenone for the treatment of severe ventricular arrhythmias.
    Rabkin SW; Rotem CE; Boroomand-Rashti K; Bar-Shlomo B
    Can Med Assoc J; 1984 Sep; 131(6):601-3. PubMed ID: 6478345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug therapy of arrhythmia in coronary cardiopathy].
    Lüderitz B
    Clin Ter; 1983 Apr; 105(1):3-11. PubMed ID: 6189663
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.